{"commentary":{"count":196,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":66,"x_thread":65,"podcast":64,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04482309\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DPT02","nct_id":"NCT04482309","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dpt02-nct04482309. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DPT02","arms":[{"description":"Biliary tract cancer","label":"Part 1 Cohort 1","type":"EXPERIMENTAL"},{"description":"Bladder cancer","label":"Part 1 Cohort 2","type":"EXPERIMENTAL"},{"description":"Cervical cancer","label":"Part 1 Cohort 3","type":"EXPERIMENTAL"},{"description":"Endometrial cancer","label":"Part 1 Cohort 4","type":"EXPERIMENTAL"},{"description":"Ovarian cancer","label":"Part 1 Cohort 5","type":"EXPERIMENTAL"},{"description":"Pancreatic cancer","label":"Part 1 Cohort 6","type":"EXPERIMENTAL"},{"description":"Rare tumors","label":"Part 1 Cohort 7","type":"EXPERIMENTAL"},{"description":"Any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer)","label":"Part 2 Cohort A","type":"EXPERIMENTAL"},{"description":"Any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer)","label":"Part 2 Cohort B","type":"EXPERIMENTAL"},{"description":"HER2 IHC 2+ or 1+ endometrial cancer","label":"Part 2 Cohort C","type":"EXPERIMENTAL"},{"description":"HER2 IHC 2+ or 1+ ovarian cancer","label":"Part 2 Cohort D","type":"EXPERIMENTAL"},{"description":"HER2 IHC 2+ or 1+ cervical cancer","label":"Part 2 Cohort E","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo Co., Ltd."],"completion_date":{"date":"2027-03-23","type":"ESTIMATED"},"conditions":["Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer","Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer"],"enrollment":{"count":477,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","type":"DRUG"}],"last_update":"2026-07-10","lead_sponsor":"AstraZeneca","official_title":"A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-03-23","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"An average of approximately 6 months"}],"references":[{"citation":"Lee JY, Oaknin A, Manso L, Gonzalez-Martin A, Lugowska I, Lorusso D, Banerjee S, Liao JB, Lu CH, Prasongsook N, Melichar B, Anoka C, Jung L, Michelini F, Puvvada S, Meric-Bernstam F, Makker V. Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses. J Gynecol Oncol. 2026 May;37(3):e65. doi: 10.3802/jgo.2026.37.e65. Epub 2026 May 6.","pmid":"42135959","type":"DERIVED"},{"citation":"Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov;41(11):4125-4139. doi: 10.1007/s12325-024-02975-x. Epub 2024 Sep 11.","pmid":"39261417","type":"DERIVED"},{"citation":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23.","pmid":"37870536","type":"DERIVED"}],"start_date":{"date":"2020-08-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","url":"https://clinicaltrials.gov/study/NCT04482309"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dpt02-nct04482309"}